Type of lung cancer-Non-small cell lung carcinoma (NSCLC) Posts on Medivizor
Navigation Menu

Type of lung cancer-Non-small cell lung carcinoma (NSCLC) Posts on Medivizor

Evaluating afatinib in patients with advanced non-small cell lung cancer who have not received EGFR TKIs

Evaluating afatinib in patients with advanced non-small cell lung cancer who have not received EGFR TKIs

Posted by on Aug 14, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the safety and effectiveness of afatinib (Gilotrif) in patients with non-small cell lung cancer (NSCLC) who have not previously received EGFR tyrosine kinase inhibitors (TKIs). Data showed that afatinib was well tolerated and improved the outcomes of these patients. Some background NSCLC...

Read More

Comparing lobectomy and sublobar resection for older patients with stage 1A NSCLC

Comparing lobectomy and sublobar resection for older patients with stage 1A NSCLC

Posted by on Jul 11, 2021 in Lung cancer | 0 comments

In a nutshell The study was carried out to assess the difference in outcomes between lobectomy (LE) and sub-lobar resection (SLR) for older patients with stage I non-small-cell lung cancer (NSCLC). The authors found that both surgeries had similar outcomes in these patients.  Some background NSCLC is responsible for 85% of lung cancer diagnoses...

Read More

Comparing alectinib to ceritinib treatment for ALK-positive non-small-cell lung cancer that failed after crizotinib treatment

Comparing alectinib to ceritinib treatment for ALK-positive non-small-cell lung cancer that failed after crizotinib treatment

Posted by on May 30, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness of ceritinib (Zykadia) and alectinib (Alecensa) in patients with ALK-positive non-small-cell lung cancer (NSCLC) who previously had a crizotinib (Xalkori) treatment failure. The data showed that both ceritinib and alectinib were effective in these patients. Some background Non-small-cell lung cancer...

Read More

Should ipilimumab and nivolumab treatment be considered before surgery in operable non-small cell lung cancer?

Should ipilimumab and nivolumab treatment be considered before surgery in operable non-small cell lung cancer?

Posted by on Apr 4, 2021 in Lung cancer | 0 comments

In a nutshell This trial was carried out to look at the effectiveness of nivolumab (Opdivo) and nivolumab plus ipilimumab (Yervoy) as neoadjuvant therapy (NAT; treatment before surgery) in treating operable non-small cell lung cancer (NSCLC). The authors found that ipilimumab and nivolumab treatment before surgery provides better...

Read More

Should immunotherapy and radiotherapy be considered as an effective treatment for non-small cell lung cancer?

Should immunotherapy and radiotherapy be considered as an effective treatment for non-small cell lung cancer?

Posted by on Apr 3, 2021 in Lung cancer | 0 comments

In a nutshell This article analyzed the safety and effectiveness of an immunotherapy (IT) and radiotherapy (RT) combination to treat patients with non-small cell lung cancer (NSCLC). The authors found that combination therapy using an immunotherapy drug such as PD-1/PD-L1 inhibitors and RT may improve the outcomes of these patients. Some background...

Read More

Nivolumab improves survival in patients with non-small cell lung cancer in the long-term.

Nivolumab improves survival in patients with non-small cell lung cancer in the long-term.

Posted by on Feb 28, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at 5-year outcomes of patients with previously treated advanced non-small-cell lung cancer (NSCLC) taking nivolumab (Opdivo) compared to docetaxel (Taxotere). The authors found that nivolumab continued to improve the outcomes of these patients after 5 years. Some background NSCLC is the most common...

Read More

Does anti-cancer therapy improve the outcomes of older patients with metastatic non-small cell lung cancer?

Does anti-cancer therapy improve the outcomes of older patients with metastatic non-small cell lung cancer?

Posted by on Feb 21, 2021 in Lung cancer | 0 comments

In a nutshell This article looked at whether anti-cancer treatments can improve the outcomes of older patients with metastatic (cancer that has spread to a new location) non-small cell lung cancer (mNSCLC). The authors found that outcomes were improved with anti-cancer therapies in these patients. Some background NSCLC is responsible...

Read More

Searching for patients to trial an experimental medication for advanced solid tumors.

Searching for patients to trial an experimental medication for advanced solid tumors.

Posted by on Jan 28, 2021 in Lung cancer | 0 comments

In a nutshell This trial is aiming to examine the safety and effectiveness of experimental treatment DF6002 alone or in combination with nivolumab (Opdivo) in the treatment of advanced solid tumors, including lung cancer. The main outcomes to be measured are drug toxicity and the response rate of patients to the drug. This trial is being carried out in...

Read More

Can a nanoparticle-based paclitaxel be more effective than a standard-preparation paclitaxel in the treatment of advanced non-small cell lung cancer?

Can a nanoparticle-based paclitaxel be more effective than a standard-preparation paclitaxel in the treatment of advanced non-small cell lung cancer?

Posted by on Jan 19, 2021 in Lung cancer | 0 comments

In a nutshell This trial compared the use of standard paclitaxel (SP; Taxol) versus a new nanoparticle micellar preparation of paclitaxel (NmP) as a first-line treatment for non-small cell lung cancer (NSCLC). The authors found that NmP had better effectiveness and safety in treating NSCLC than SP.  Some...

Read More

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Posted by on Dec 30, 2020 in Melanoma | 0 comments

In a nutshell The study evaluated the timing of radiotherapy (RT) and immune-checkpoint therapy (ICT) on the outcomes of patients with brain metastasis (BrM) resulting from melanoma and non-small cell lung cancer (NSCLC). The authors found that RT and ICT given at the same time may improve response and delay recurrence in these patients. Some...

Read More